OncoMatch/Clinical Trials/NCT03824652
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Is NCT03824652 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP. Patients consented to the study will be randomly assigned to either continue their usual diets (control arm) or to the walnut arm for 4-10 weeks depending on the window between their consent date and the date for RP.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Demographics
Prior therapy
Cannot have received: hormone therapy
History of receiving hormone therapy or antiandrogen therapy.
Cannot have received: 5-alpha reductase inhibitor
Use of 5-alpha reductase inhibitors in the past 6 months.
Cannot have received: radiation therapy
Prior prostate radiotherapy (external beam or brachytherapy)
Cannot have received: cryotherapy
prior prostate cryotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
- Durham VA Medical Center · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03824652 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hormone therapy, 5-alpha reductase inhibitor, radiation therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages